CA
SRPT icon

Crewe Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Crewe Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-155
Closed -$3.34K – 1140
2025
Q4 		$3.34K Hold
155
– – ﹤0.01% 801
2025
Q3 		$2.99K Buy
+155
New +$2.76K ﹤0.01% 794
2023
Q4 		– Sell
-1
Closed -$122 – 660
2023
Q3 		$122 Buy
+1
New +$113 ﹤0.01% 532
2023
Q2 		– Sell
-212
Closed -$29.2K – 995
2023
Q1 		$29.2K Sell
212
-25
-11% -$3.24K ﹤0.01% 372
2022
Q4 		$30.7K Hold
237
– – ﹤0.01% 359
2022
Q3 		$26K Hold
237
– – ﹤0.01% 416
2022
Q2 		$18K Buy
+237
New +$17.4K ﹤0.01% 454
2021
Q1 		– Sell
-6
Closed -$1K – 484
2020
Q4 		$1K Sell
6
-9
-60% -$1.33K ﹤0.01% 436
2020
Q3 		$2K Buy
+15
New +$2.28K ﹤0.01% 534

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Crewe Advisors's SRPT Position: Q1 2026 in Review

Crewe Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 155 shares — an estimated $3.34K sold.

Crewe Advisors first reported a position in SRPT in Q3 2020 and held it in 9 quarters. The position peaked at $30.7K in Q4 2022. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Crewe Advisors reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Crewe Advisors sold 155 Sarepta Therapeutics shares in Q1 2026, an estimated $3.34K.
  • Crewe Advisors first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 9 quarters.
  • Crewe Advisors's Sarepta Therapeutics position peaked at $30.7K in Q4 2022.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Crewe Advisors's 13F filing for Q1 2026, filed 7 May 2026.